Multi-Million-Dollar Non-Dilutive Deal Fuels Amprion’s Neuro Testing Push

For high-growth healthtech startups, dilution can be a bitter pill. Amprion’s new multi-million-dollar funding from Decathlon Capital Partners shows how revenue-based financing can fuel expansion without giving away equity. The deal underscores a growing trend among venture-backed diagnostics companies seeking operational flexibility while preparing for larger institutional rounds or an eventual exit.

Amprion, a San Diego-based diagnostics company, announced on July 8, 2026 that it has secured a multi-million-dollar growth investment from Decathlon Capital Partners to expand its testing capacity for neurodegenerative disorders. The funding arrives as demand climbs for the company’s seed-amplification assay, SAAmplify-aSYN, which is currently the only commercially available test of its kind to aid diagnosis of synucleinopathies—including Parkinson’s disease, Lewy body dementia, and Alzheimer’s with Lewy pathology. What stands out in this deal is the structure: it is non-dilutive, meaning existing shareholders avoid ownership erosion and management retains full governance control. Instead, Decathlon Capital Partners provides revenue-based funding, a model in which repayment flexes with the company’s top-line performance.

“

Amprion’s new multi-million-dollar funding from Decathlon Capital Partners shows how revenue-based financing can fuel expansion without giving away equity.

The investment highlights both the capital needs of precision diagnostics ventures and the appetite among specialty lenders to back life sciences companies with growing commercial traction. Amprion’s CEO Russ Lebovitz framed the infusion as essential to meet an accelerating global demand for pathology-based insights, while Decathlon’s Managing Director Matt Hoffman pointed to the critical unmet need for earlier and more accurate diagnosis of neurodegenerative diseases. Although specific deal terms—total amount, revenue-share percentage, and duration—were not disclosed, the “multi-million-dollar” descriptor and the reference to “tailored financing package” suggest a substantial, custom-engineered facility likely pegged to Amprion’s current sales trajectory.

The broader market context is favorable. The neurodegenerative diagnostics sector is projected to grow sharply as the global burden of Alzheimer’s and Parkinson’s rises with aging populations. Seed amplification assays represent a technological leap: rather than relying solely on clinical symptoms or indirect biomarkers, they detect misfolded protein aggregates—hallmarks of synucleinopathies—with high sensitivity. Amprion’s test has been adopted by researchers and clinicians in multiple countries, positioning it as a first-mover in a niche with high barriers to entry due to proprietary IP and laboratory complexity. Scaling its capacity will directly affect how many patients gain access to a confirmatory test that can distinguish between otherwise overlapping dementias.

From a financial perspective, the choice of revenue-based financing is strategic. Early-stage biotech and diagnostics firms often dilute ownership through successive equity rounds, eventually leaving founders and early investors with diminished stakes. By opting for a non-dilutive structure, Amprion maintains a cleaner cap table as it prepares for potential larger institutional equity rounds, strategic partnerships, or an eventual acquisition. However, the trade-off is a claim on future cash flows; if revenue grows at a slower pace, the annual repayment terms could strain working capital. Decathlon Capital Partners, a specialist in this type of financing, assumes that risk with the expectation that Amprion’s revenue will outpace the cost of capital.